Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Comparison of CR rates between DNMT3A R882 mutation and wild type patients after one or two courses of induction therapy

From: Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients

Chemotherapy cycles Total
CR/n (%)
R882 wild-type
CR/n (%)
R882 mutation
CR/n (%)
OR (95% CI) P value
One cycle 357/864 (41.32) 336/791 (42.48) 21/73 (28.77) 1.829 (1.081–3.094) 0.023
Two cycles 601/864 (69.56) 556/791 (70.29) 45/73 (61.64) 1.472 (0.897–2.417) 0.124
  1. CR complete response, R882 arginine 882, OR odds ratio, CI confidence interval
  2. Italic values indicate significance of P value (P < 0.05)